始めましょう
ReutersReuters

Linvoseltamab In Combination With Carfilzomib Or Bortezomib Shows Promising Initial Results In Earlier Lines Of Treatment For Relapsed/Refractory Multiple Myeloma

Refinitiv1分未満で読めます
REGN

Regeneron Pharmaceuticals Inc REGN:

  • LINVOSELTAMAB IN COMBINATION WITH CARFILZOMIB OR BORTEZOMIB SHOWS PROMISING INITIAL RESULTS IN EARLIER LINES OF TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

  • REGENERON PHARMACEUTICALS INC - 90% OBJECTIVE RESPONSE RATE IN LINVOSELTAMAB AND CARFILZOMIB COMBINATION

Reuters米国株
refinitivrefinitiv
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
ログイン、もしくは永年無料のアカウントを作成して、このニュースを読みましょう

Reutersからその他のニュース